Agenus获得22M抵押贷款,重新分配资金,重点用于结肠癌药物,使库存增加16.3%。 Agenus secures $22M mortgage, reallocates funds to focus on colorectal cancer drug, boosting stock by 16.3%.

Agenus生物制药公司以其在加利福尼亚伯克利和瓦卡维尔的设施为后盾,取得了2 200万美元的抵押贷款,提高了其现金状况。 Biopharmaceutical company Agenus has secured a $22 million mortgage backed by its facilities in Berkeley and Vacaville, California, boosting its cash position. 该公司还正在调整业务,将重点放在研制直肠癌药物上,目的是在2025年将其现金燃烧减少到约1亿美元。 The company is also realigning its operations to focus on developing a colorectal cancer drug, aiming to reduce its cash burn to about $100 million in 2025. Agenus股份在宣布后上升16.3%,达到3.93美元。 Agenus shares rose by 16.3% to $3.93 following the announcement.

文章

Benzinga

Market Screener

Biztoc

Market Screener

-- 显示更少 --

延伸阅读

相关故事